Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI and 3D imaging join forces to spot breast cancer faster

NCT ID NCT07491055

Diagnosis Sponsor: Jean Seely Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether combining a special 3D mammogram (wide-angle tomosynthesis) with an AI tool helps doctors diagnose breast cancer more accurately and confidently. About 1,400 women with breast symptoms or who were called back after a screening mammogram will take part. The goal is to see if this technology reduces the need for extra tests and improves detection.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 1,400 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Apr 2026

An estimate. Start dates often move.

Expected to finish

Dec 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Participants will be adults receiving diagnostic breast imaging at The Ottawa Hospital Breast Imaging Center. The study population consists of consecutive patients referred for assessment of screen-detected abnormalities or clinical breast symptoms, who undergo routine diagnostic mammography performed on the Siemens MAMMOMAT B.brilliant system.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Provides verbal consent to participate. * Referred for diagnostic breast imaging at The Ottawa Hospital due to: * Recall from a screening mammogram for a soft-tissue lesion, or * Breast symptoms (e.g., palpable mass, nipple discharge) with last screening mammogram \>6 months prior. * Able to undergo wide-angle DBT and Insight 2D views on the Siemens MAMMOMAT B.brilliant system. Exclusion Criteria: * Presence of breast implants. * History of breast surgery on the breast being evaluated. * Required imaging views not obtained (wide-angle DBT + Insight 2D views). * Unable or unwilling to complete the imaging procedure per standard protocol. * Declines the use of AI on the mammography unit (patients who decline are imaged on another machine and not included).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast neoplasms diagnosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Breast neoplasms diagnosis Brest cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.